Xencor, Inc Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss
Xencor, Inc (XNCR) reported Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss of -$5.00 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-08.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2016-03-08
- Xencor, Inc marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2015-12-31 was -$1.00K.
- Xencor, Inc marketable securities, unrealized gain (loss), excluding other-than-temporary impairment loss for fiscal 2015 was -$5.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Unrealized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|
| 2015-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-08 | -$5.00K 10-K · filed 2016-03-08 | |
| 2015-09-30 | -$4.00K 10-Q · filed 2015-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |